Glaukos share price today
(NASDAQ: GKOS)

Name: Glaukos Share Price Today (NASDAQ: GKOS) - Glaukos Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Glaukos share price is $161.22 & ₹13,943.92 as on 24 Jan 2025, 2.30 'hrs' IST

$161.22

▲

1.1

(0.69%)

Market is closed - opens 8 PM, 24 Jan 2025

View live Glaukos share price in Dollar and Rupees. Guide to invest in Glaukos stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Glaukos, along with analyst recommendations, forecasts, and comprehensive financials.

Glaukos share price movements

Today's Low: $158.33
Today's High: $163.58
$161.22
1.8%
Downside
Day's Volatility :3.21%
Upside
1.44%
52 Weeks Low: $83.90
52 Weeks High: $161.31
$161.22
47.96%
Downside
52 Weeks Volatility :47.99%
Upside
0.05%

Glaukos Returns

Period	Glaukos Corp	Sector (Health Care)	Index (Russel 2000)
3 Months	22.61%	-5.5%	0.0%
6 Months	33.63%	-4.3%	0.0%
1 Year	76.54%	1.6%	0.0%
3 Years	216.88%	9.8%	-11.0%

Glaukos Key Statistics

in dollars & INR

Previous Close	$160.12
Open	$159.28
Today's High	$163.58
Today's Low	$158.325
Market Capitalization	$8.8B
Today's Volume	$520.6K
52 Week High	$163.58
52 Week Low	$83.9
Revenue TTM	$360.3M
EBITDA	$-80.7M
Earnings Per Share (EPS)	$-2.93
Profit Margin	-41.51%
Quarterly Earnings Growth YOY	18.96%
Return On Equity TTM	-26.1%

How to invest in Glaukos Stock (GKOS) from India?

It is very easy for Indian residents to invest directly in Glaukos from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Glaukos stock in both Indian Rupees (INR) and US Dollars (USD). Search for Glaukos or GKOS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Glaukos or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Glaukos shares which would translate to 0.005 fractional shares of Glaukos as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Glaukos, in just a few clicks!

Returns in Glaukos for Indian investors in Rupees

Investment Value

₹1,00,000

Glaukos investment value today

Current value as on today

₹1,81,805

Returns

₹81,805

(+81.81%)

Returns from Glaukos Stock

₹77,751 (+77.75%)

Dollar Returns

₹4,054 (+4.05%)

Indian investors sentiment towards Glaukos

-40%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Search volume for Glaukos on INDmoney from India has reduced in the last 30 days as on Jan 24, 2025. -40% less investors are searching Glaukos in the last 30 days versus the previous period.

Global Institutional Holdings in Glaukos

BlackRock Inc
15.38%
FMR Inc
11.94%
Vanguard Group Inc
10.65%
Wellington Management Company LLP
3.96%
State Street Corp
3.54%
Ameriprise Financial Inc
2.97%

Analyst Recommendation on Glaukos

Buy

75%Buy

25%Hold

0%Sell

Based on 20 Wall street analysts offering stock ratings for Glaukos(by analysts ranked 0 to 5 stars)

Based on 20 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Glaukos

What analysts predicted

Downside of 3.7%

Target:

$155.25

Current:

$161.22

Insights on Glaukos

Price Movement
In the last 1 year, GKOS stock has moved up by 73.0%
Increasing Revenue
Revenue is up for the last 5 quarters, 78.04M → 96.67M (in $), with an average increase of 5.2% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -50.54M → -21.40M (in $), with an average increase of 136.1% per quarter

Glaukos Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$181.3M	↑ 13.83%
Net Income	$-13.0M	↑ 13977.17%
Net Profit Margin	-7.14%	↓ 7.08%

	FY19	Y/Y Change
Revenue	$237.0M	↑ 30.73%
Net Income	$15.4M	↓ 219.1%
Net Profit Margin	6.51%	↑ 13.65%

	FY20	Y/Y Change
Revenue	$225.0M	↓ 5.07%
Net Income	$-120.3M	↓ 880.26%
Net Profit Margin	-53.5%	↓ 60.01%

	FY21	Y/Y Change
Revenue	$294.0M	↑ 30.7%
Net Income	$-49.6M	↓ 58.79%
Net Profit Margin	-16.87%	↑ 36.63%

	FY22	Y/Y Change
Revenue	$282.9M	↓ 3.79%
Net Income	$-99.2M	↑ 100.02%
Net Profit Margin	-35.07%	↓ 18.2%

	FY23	Y/Y Change
Revenue	$314.7M	↑ 11.26%
Net Income	$-134.7M	↑ 35.75%
Net Profit Margin	-42.79%	↓ 7.72%

	Q2 FY23	Q/Q Change
Revenue	$80.4M	↑ 8.8%
Net Income	$-32.8M	↓ 5.24%
Net Profit Margin	-40.81%	↑ 6.05%

	Q3 FY23	Q/Q Change
Revenue	$78.0M	↓ 2.92%
Net Income	$-30.4M	↓ 7.22%
Net Profit Margin	-39.01%	↑ 1.8%

	Q4 FY23	Q/Q Change
Revenue	$82.4M	↑ 5.53%
Net Income	$-36.8M	↑ 20.81%
Net Profit Margin	-44.65%	↓ 5.64%

	Q1 FY24	Q/Q Change
Revenue	$85.6M	↑ 3.95%
Net Income	$-40.8M	↑ 11.04%
Net Profit Margin	-47.7%	↓ 3.05%

	Q2 FY24	Q/Q Change
Revenue	$95.7M	↑ 11.76%
Net Income	$-50.5M	↑ 23.77%
Net Profit Margin	-52.82%	↓ 5.12%

	Q3 FY24	Q/Q Change
Revenue	$96.7M	↑ 1.02%
Net Income	$-21.4M	↓ 57.64%
Net Profit Margin	-22.15%	↑ 30.67%

	FY18	Y/Y Change
Profit	$156.2M	↑ 13.02%

	FY19	Y/Y Change
Profit	$198.4M	↑ 27.01%

	FY20	Y/Y Change
Profit	$133.2M	↓ 32.84%

	FY21	Y/Y Change
Profit	$227.4M	↑ 70.66%

	FY22	Y/Y Change
Profit	$213.9M	↓ 5.94%

	FY23	Y/Y Change
Profit	$239.1M	↑ 11.81%

	Q2 FY23	Q/Q Change
Profit	$60.3M	↑ 8.0%

	Q3 FY23	Q/Q Change
Profit	$59.5M	↓ 1.26%

	Q4 FY23	Q/Q Change
Profit	$63.5M	↑ 6.61%

	Q1 FY24	Q/Q Change
Profit	$65.4M	↑ 2.98%

	Q2 FY24	Q/Q Change
Profit	$73.1M	↑ 11.9%

	Q3 FY24	Q/Q Change
Profit	$74.1M	↑ 1.29%

	FY18	Y/Y Change
Operating Cash Flow	$18.9M	↓ 26.05%
Investing Cash Flow	$-26.4M	↑ 125.12%
Financing Cash Flow	$21.6M	↑ 362.31%

	FY19	Y/Y Change
Operating Cash Flow	$-369.0K	↓ 101.96%
Investing Cash Flow	$43.4M	↓ 264.49%
Financing Cash Flow	$-9.6M	↓ 144.7%

	FY20	Y/Y Change
Operating Cash Flow	$-23.0M	↑ 6129.81%
Investing Cash Flow	$-205.1M	↓ 572.21%
Financing Cash Flow	$262.5M	↓ 2822.05%

	FY21	Y/Y Change
Operating Cash Flow	$24.7M	↓ 207.48%
Investing Cash Flow	$-58.2M	↓ 71.6%
Financing Cash Flow	$39.3M	↓ 85.05%

	FY22	Y/Y Change
Operating Cash Flow	$-33.1M	↓ 233.9%
Investing Cash Flow	$44.8M	↓ 176.9%
Financing Cash Flow	$6.3M	↓ 84.08%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-8.2M	↓ 73.47%
Investing Cash Flow	$26.0M	↓ 287.62%
Financing Cash Flow	$-880.0K	↓ 176.39%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-8.2M	↑ 0.09%
Investing Cash Flow	$14.9M	↓ 42.6%
Financing Cash Flow	$7.5M	↓ 948.52%

Glaukos Technicals Summary

Sell

Neutral

Buy

Glaukos is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Glaukos Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Glaukos Corp	5.89%	33.63%	76.54%	216.88%	183.25%
Medtronic Plc	7.73%	11.61%	2.39%	-15.68%	-26.33%
Edwards Lifesciences Corp.	-8.41%	10.69%	-6.13%	-36.94%	-9.52%
Boston Scientific Corp.	10.15%	33.89%	64.9%	135.97%	135.19%
Stryker Corporation	5.32%	17.73%	25.19%	56.65%	81.96%
Abbott Laboratories	2.63%	11.92%	4.74%	-4.45%	31.47%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Glaukos Corp	NA	NA	1.64	-1.83	-0.26	-0.08	NA	12.13
Medtronic Plc	27.03	27.03	1.5	5.46	0.08	0.04	0.03	38.29
Edwards Lifesciences Corp.	26.66	26.66	6.43	2.55	0.19	0.11	NA	16.18
Boston Scientific Corp.	83.4	83.4	1.79	2.46	0.09	0.05	NA	14.05
Stryker Corporation	42.47	42.47	2.68	12.06	0.19	0.07	0.01	52.86
Abbott Laboratories	34.45	34.45	2.2	4.67	0.15	0.06	0.02	22.94

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Glaukos Corp	Buy	$8.8B	183.25%	NA	-41.51%
Medtronic Plc	Buy	$113.3B	-26.33%	27.03	12.06%
Edwards Lifesciences Corp.	Buy	$40.7B	-9.52%	26.66	65.86%
Boston Scientific Corp.	Buy	$148.7B	135.19%	83.4	11.26%
Stryker Corporation	Buy	$150.9B	81.96%	42.47	16.34%
Abbott Laboratories	Buy	$202.6B	31.47%	34.45	13.99%

Glaukos Dividend announcements

Glaukos Earnings
Glaukos’s price-to-earnings ratio stands at None
Read More

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Organization	Glaukos
Employees	907
CEO	Mr. Thomas William Burns
Industry	Health Technology

Management People of Glaukos

Name	Title
Mr. Thomas William Burns	Chairman & CEO
Mr. Joseph E. Gilliam	President & COO
Mr. Alex R. Thurman	Senior VP & CFO
Dr. Tomas Navratil Ph.D.	Chief Development Officer
Dr. Mory Gharib Ph.D.	Co-Founder
Mr. Christopher William Lewis	Vice President of Investor Relations & Corporate Affairs
Mr. Robert L. Davis J.D.	Senior VP, General Counsel & Business Development
Ms. Diana A. Scherer	VP of Compliance & Deputy General Counsel
Ms. Michele M. Allegretto	Senior Vice President of Human Resources
Mr. Chris M. Calcaterra	Executive Vice President of Global Commercial Operations

Important FAQs about investing in Glaukos (GKOS) from India :

What is Glaukos share price today?

Glaukos share price today stands at $161.22, Open: $159.28 ; Previous Close: $160.12 ; High: $163.58 ; Low: $158.33 ; 52 Week High: $161.31 ; 52 Week Low: $83.90. The stock opens at $159.28, after a previous close of $160.12. The stock reached a daily high of $163.58 and a low of $158.33, with a 52-week high of $161.31 and a 52-week low of $83.90.

Can Indians buy Glaukos shares?

Yes, Indians can invest in the Glaukos (GKOS) from India.

With INDmoney, you can buy Glaukos at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Glaukos at zero transaction cost.

How can I buy Glaukos shares from India?

It is very easy to buy Glaukos from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Glaukos be purchased?

Yes, you can buy fractional shares of Glaukos with INDmoney app.

What are the documents required to start investing in Glaukos stocks?

To start investing in Glaukos, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.